Pfizer spends billions to develop new drugs. It’s not satisfied. So it’s launching a startup

Updated on


There’s a popular theory about the limitations of global pharma companies: For all their skyscrapers and strategy reviews and private jets, they’re simply too knotted up in bureaucracy to realize how many great drugs are gathering dust in their vaults. Now, the biggest of Big Pharma is out do do something about that. Pfizer, home to…

Leave a Comment